KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Capital Expenditures: 2018-2025

Historic Capital Expenditures for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Sep 2025 value amounting to $65,000.

  • Aurinia Pharmaceuticals' Capital Expenditures fell 23.53% to $65,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $236,000, marking a year-over-year decrease of 54.96%. This contributed to the annual value of $281,000 for FY2024, which is 60.86% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Capital Expenditures stood at $65,000 for Q3 2025, which was down 33.67% from $98,000 recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Capital Expenditures peaked at $1.0 million during Q1 2021, and registered a low of -$105,000 during Q3 2023.
  • Over the past 3 years, Aurinia Pharmaceuticals' median Capital Expenditures value was $85,000 (recorded in 2024), while the average stood at $107,182.
  • Its Capital Expenditures has fluctuated over the past 5 years, first spiked by 1,108.14% in 2021, then plummeted by 362.50% in 2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Capital Expenditures (Quarterly) stood at $159,000 in 2021, then tumbled by 74.84% to $134,000 in 2022, then surged by 123.13% to $299,000 in 2023, then crashed by 81.27% to $56,000 in 2024, then declined by 23.53% to $65,000 in 2025.
  • Its last three reported values are $65,000 in Q3 2025, $98,000 for Q2 2025, and $17,000 during Q1 2025.